Triterpenoids as new promising anticancer drugs

Area of Science:

• Natural Products Chemistry
• Medicinal Chemistry
• Pharmacology

Background:

• Triterpenoids are a diverse class of organic compounds with over 20,000 known natural varieties.
• Several triterpenoids, such as ursolic acid and betulinic acid, exhibit significant antitumor and anti-inflammatory activities.
• Synthetic triterpenoid derivatives have been developed to enhance their therapeutic potential.

Purpose of the Study:

• To explore the potential of synthetic triterpenoid derivatives in cancer therapy.
• To investigate the antitumor activities of specific compounds like CDDO, CDDO-Me, and betulinic acid.
• To understand the molecular mechanisms underlying triterpenoid-mediated anti-cancer effects.

Main Methods:

• Synthesis of novel triterpenoid derivatives, including cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO), CDDO-Me, and CDDO-Im.
• Evaluation of antitumor activities of selected triterpenoids and their synthetic derivatives.
• Assessment of mechanisms such as nuclear factor-kappaB (NF-κB) activation inhibition, apoptosis induction, and anti-angiogenesis.

Main Results:

• CDDO, CDDO-Me, and betulinic acid demonstrated promising antitumor activities.
• These compounds are currently undergoing phase I clinical trials.
• Triterpenoids function through multiple pathways, including blocking NF-κB, inducing apoptosis, and inhibiting angiogenesis.

Conclusions:

• Synthetic triterpenoids, particularly CDDO derivatives and betulinic acid, represent a promising avenue for cancer treatment.
• Further clinical evaluation is warranted to establish their efficacy and safety.
• The multifunctional nature of triterpenoids offers a versatile approach to targeting cancer progression.